Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
Movano Health (Nasdaq: MOVE) has received a notice of non-compliance from Nasdaq due to failing to file its Q2 2025 Form 10-Q by the August 14, 2025 deadline. The company appealed its previous delisting determination at a Nasdaq Hearing Panel on August 19, 2025, presenting a compliance plan to address both the filing requirement and the $1.00 minimum bid price requirement.
As part of its compliance efforts, Movano Health engaged RBSM LLP as its new independent registered public accounting firm on August 13, 2025. The company is currently awaiting the Panel's determination, with no guarantee that it will be granted a trading suspension stay or maintain its Nasdaq listing.
Movano Health (Nasdaq: MOVE) ha ricevuto una notifica di non conformit脿 da Nasdaq per non aver depositato il modulo 10-Q relativo al secondo trimestre 2025 entro la scadenza del 14 agosto 2025. La societ脿 ha fatto appello alla precedente decisione di delisting davanti a un Nasdaq Hearing Panel il 19 agosto 2025, presentando un piano di conformit脿 volto a risolvere sia l'obbligo di deposito sia il requisito del prezzo minimo per azione di $1,00.
Nel quadro delle proprie azioni correttive, Movano Health ha nominato RBSM LLP come nuovo revisore contabile registrato indipendente in data 13 agosto 2025. L'azienda 猫 in attesa della decisione del Panel, senza alcuna garanzia di ottenere una sospensione della negoziazione o di mantenere la quotazione su Nasdaq.
Movano Health (Nasdaq: MOVE) recibi贸 una notificaci贸n de incumplimiento por parte de Nasdaq por no presentar su Formulario 10-Q del segundo trimestre de 2025 antes de la fecha l铆mite del 14 de agosto de 2025. La compa帽铆a apel贸 la previa determinaci贸n de exclusi贸n en un Panel de Audiencias de Nasdaq el 19 de agosto de 2025, presentando un plan de cumplimiento para abordar tanto el requisito de presentaci贸n como el requisito de precio m铆nimo por acci贸n de $1.00.
Como parte de sus esfuerzos de cumplimiento, Movano Health contrat贸 a RBSM LLP como su nueva firma contable p煤blica registrada e independiente el 13 de agosto de 2025. La compa帽铆a est谩 a la espera de la determinaci贸n del Panel, sin garant铆a de que se le conceda una suspensi贸n de negociaci贸n o de que mantenga su cotizaci贸n en Nasdaq.
Movano Health (雮橃姢雼�: MOVE)電� 2025雲� 8鞗� 14鞚缄箤歆� 2025雲� 2攵勱赴 Form 10-Q毳� 鞝滌稖頃橃 鞎婌晞 雮橃姢雼レ溂搿滊秬韯� 攵堨澊頄� 韱奠毳� 氚涭晿鞀惦媹雼�. 須岇偓電� 2025雲� 8鞗� 19鞚� 雮橃姢雼� 鞁寪鞙勳洂須�(Nasdaq Hearing Panel)鞐� 於滌劃頃� 鞚挫爠 靸侅灔韽愳 瓴办爼鞐� 雽�頃� 頃唽頃橁碃, 鞝滌稖 鞚橂鞕� 欤茧嫻 斓滌爛 鞛呾鞍臧�瓴� $1.00 鞖旉贝鞚� 頃搓舶頃橁赴 鞙勴暅 旎错攲霛检澊鞏胳姢 瓿勴殟鞚� 鞝滌嫓頄堨姷雼堧嫟.
旎错攲霛检澊鞏胳姢 臁办箻鞚� 鞚柬櫂鞙茧 Movano Health電� 2025雲� 8鞗� 13鞚检瀽搿� 靸堧鞖� 霃呺 瓿奠澑須岅硠氩曥澑 RBSM LLP毳� 靹犾瀯頄堨姷雼堧嫟. 須岇偓電� 順勳灛 鞙勳洂須岇潣 瓴办爼鞚� 旮半嫟毽碃 鞛堨溂氅�, 瓯半灅欷戨嫧 鞙犾槇雮� 雮橃姢雼� 靸侅灔 鞙犾臧� 氤挫灔霅橃電� 鞎婌姷雼堧嫟.
Movano Health (Nasdaq: MOVE) a re莽u un avis de non-conformit茅 de la part de Nasdaq pour ne pas avoir d茅pos茅 son formulaire 10-Q du deuxi猫me trimestre 2025 avant la date limite du 14 ao没t 2025. La soci茅t茅 a fait appel de la d茅cision de radiation ant茅rieure devant un Nasdaq Hearing Panel le 19 ao没t 2025, pr茅sentant un plan de conformit茅 visant 脿 traiter 脿 la fois l'obligation de d茅p么t et l'exigence de prix d'offre minimum de 1,00 $.
Dans le cadre de ses efforts de conformit茅, Movano Health a engag茅 RBSM LLP comme nouveau cabinet d'expertise comptable ind茅pendant enregistr茅 le 13 ao没t 2025. La soci茅t茅 attend la d茅cision du Panel, sans garantie d'obtenir une suspension des n茅gociations ni de conserver sa cotation sur Nasdaq.
Movano Health (Nasdaq: MOVE) hat von der Nasdaq eine Nichtkonformit盲tsmitteilung erhalten, weil das Form 10-Q f眉r das zweite Quartal 2025 nicht bis zur Frist am 14. August 2025 eingereicht wurde. Das Unternehmen legte am 19. August 2025 vor einem Nasdaq Hearing Panel Berufung gegen die fr眉here Delisting-Entscheidung ein und stellte einen Compliance-Plan vor, um sowohl die Einreichungsanforderung als auch die Mindestgebotspreis-Anforderung von $1,00 zu erf眉llen.
Im Rahmen der Compliance-Ma脽nahmen setzte Movano Health am 13. August 2025 RBSM LLP als neue unabh盲ngige eingetragene Wirtschaftspr眉fungsgesellschaft ein. Das Unternehmen wartet derzeit auf die Entscheidung des Panels, ohne Garantie f眉r eine Aussetzung des Handels oder den Verbleib an der Nasdaq.
- Engagement of new accounting firm RBSM LLP to address compliance issues
- Company has submitted a formal compliance plan to Nasdaq
- Failure to file Q2 2025 Form 10-Q by deadline
- Risk of potential delisting from Nasdaq
- Non-compliance with $1.00 minimum bid price requirement
- Uncertainty regarding Panel's determination
The Company appealed its previously announced delisting determination at a hearing with the Nasdaq Hearing Panel (the "Panel") on August 19, 2025 during which the Company submitted a plan to regain compliance with the Filing Requirement and the
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health, maker of the Evie Ring (), is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.
Movano Health's proprietary technologies and wearable medical device solutions will soon enable the use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit .
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements relating to the Company's plan to regain compliance with Nasdaq's rules and the timing thereof. Actual results could differ materially from those expressed in or implied by the forward-looking statements due to a number of risks and uncertainties, including but not limited to Nasdaq's acceptance of the Company's compliance plan, and the duration of any extension that may be granted by Nasdaq途 the potential inability to meet Nasdaq's requirements途 uncertainties associated with the Company's preparation of the delinquent filings途 and the possibility of additional delays in the filing of the delinquent filing and the Company's other SEC filings. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View original content to download multimedia:
SOURCE Movano
FAQ
Why is Movano Health (MOVE) at risk of being delisted from Nasdaq?
What steps has Movano Health (MOVE) taken to address its Nasdaq compliance issues?
When did Movano Health (MOVE) receive the Nasdaq deficiency notice?
What are the potential outcomes for Movano Health's (MOVE) Nasdaq listing status?
